Vaginal microbiota, vulvar vaginal atrophy, and vaginal signs in postmenopausal women

Maturitas ◽  
2019 ◽  
Vol 124 ◽  
pp. 149
Author(s):  
Svetlana Yureneva ◽  
Yelena Yeprikyan ◽  
Andrey Donnikov ◽  
Larisa Ezhova ◽  
Dmitrij Trofimov
Maturitas ◽  
2021 ◽  
Author(s):  
Claudio Foschi ◽  
Stefania Alvisi ◽  
Maurizio Baldassarre ◽  
Luca Laghi ◽  
Giulia Gava ◽  
...  

Climacteric ◽  
2018 ◽  
Vol 21 (2) ◽  
pp. 174-178 ◽  
Author(s):  
H. A. Torky ◽  
A. Taha ◽  
H. Marie ◽  
E. El-Desouky ◽  
O. Raslan ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ilnaz Zohrabi ◽  
Parvin Abedi ◽  
Somayeh Ansari ◽  
Elham Maraghi ◽  
Nader Shakiba Maram ◽  
...  

Author(s):  
Meena Dayal ◽  
Preeti Yadav

ABSTRACT Aim As there is dilemma for treatment of postmenopausal vaginal atrophy, effort has been made to review the literature for the same. Background About half of all postmenopausal women will experience symptoms related to urogenital atrophy. Vaginal atrophy becomes clinically apparent 4 to 5 years after menopause, and subjective complaints as well as objective changes are present in 25 to 50% of all postmenopausal women. Review results Measures could be taken for not only treatment but also prevention of atrophy before symptoms become troublesome, but establishment of this prevention principle globally would require a formal cost-effective analysis and further research. Conclusion Treatment with local estrogen is simple, safe, and can transform a woman’s quality of life. Clinical significance Women experiencing sexual and urinary symptoms as a consequence of vaginal atrophy should be diagnosed and treated without delay in order to avoid a cascade of events which do not resolve spontaneously. How to cite this article Yadav P, Dayal M. Management of Postmenopausal Vaginal Atrophy: Review of Literature. J South Asian Feder Menopause Soc 2017;5(1):51-57.


Author(s):  
JoAnn V. Pinkerton ◽  
Jan L. Shifren ◽  
June La Valleur ◽  
Amy Rosen ◽  
Mary Roesinger ◽  
...  

2017 ◽  
Vol 23 (4) ◽  
pp. 171-176 ◽  
Author(s):  
Masumeh Ghazanfarpour ◽  
Paymaneh Shokrollahi ◽  
Talat Khadivzadeh ◽  
Nosrat Baharian Sharghi ◽  
Khadijeh Mirzaii Najmabadi ◽  
...  

Objectives This study was conducted to evaluate the effects of orally administered fennel on vaginal atrophy. Materials and methods In this double-blind, randomized, placebo-controlled trial, 60 postmenopausal women living in Mashhad, Iran, were randomly divided into an oral fennel group (n = 30) and a placebo group (n = 30). The Maturation Vaginal Index and maturation values were measured once at baseline and again upon a three-month follow-up. Results The paired t-test showed statistically significant changes in the Maturation Vaginal Index (i.e. a decline in the parabasal cells and an increase in the intermediate and superficial cells) and maturation values in both the fennel and placebo groups at the end of the trial compared to at baseline. Nonetheless, no significant differences were observed in the percentages of the parabasal (P = 0.191), intermediate (P = 0.219) and superficial (P = 0.82) cells, which was also the case for the maturation values (P = 0.64). Conclusion Fennel had no significant positive effects on vaginal atrophy in postmenopausal women. Nonetheless, more studies are recommended to be conducted using higher doses of fennel and larger sample sizes so as to verify the results of this study.


2013 ◽  
Vol 1 (2) ◽  
pp. 44-53 ◽  
Author(s):  
Irwin Goldstein ◽  
Brian Dicks ◽  
Noel N. Kim ◽  
Rose Hartzell

Sign in / Sign up

Export Citation Format

Share Document